- In June 2022, Roivant Sciences and Pfizer announced the launch of Priovant Therapeutics, a new venture focused on the development and commercialization of innovative therapies aimed at autoimmune diseases with the highest levels of morbidity and mortality. This strategic collaboration underscores the growing commitment to addressing critical gaps in the autoimmune treatment landscape, enhancing the global autoimmune treatment market by introducing novel, targeted therapies that could significantly improve patient outcomes for some of the most challenging autoimmune conditions
- In February 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted Revolo Biotherapeutics approval to initiate two Phase II clinical trials for its autoimmune disease treatment candidate, "1805." This approval marks a significant advancement in the development of innovative therapies for autoimmune diseases, reinforcing the ongoing progress within the global autoimmune treatment market
- In January 2021, Exagen Inc., a company dedicated to transforming the care continuum for patients with autoimmune diseases, announced that all AVISE test options, including SLE Prognostic, Lupus, CTD, SLE Monitor, APS, MTX, Vasculitis AAV, and HCQ, had been designated as in-network services with Tufts Health Plan, a renowned academic medical center globally. The collaboration is particularly relevant to the global autoimmune treatment market, as it fosters improved patient outcomes and contributes to the growing demand for diagnostic and therapeutic innovations in autoimmune disease management
- In August 2019, the U.S. FDA granted approval for PerkinElmer, Inc.'s EUROIMMUN Anti-Tissue Transglutaminase ELISA, a diagnostic tool designed to assist physicians in confirming or ruling out a diagnosis of celiac disease. The relevance to the global autoimmune treatment market lies in the growing demand for precise diagnostic technologies, which play a crucial role in enabling timely and effective treatment for autoimmune conditions, ultimately driving market growth and innovation
- In October 2021, Exagen Inc., a leading provider of autoimmune testing solutions, announced that its AVISE CTD and AVISE Lupus tests are now covered services under a contract with Inland Empire Health Plan (IEHP), benefiting over 1.4 million members. This development is significant for the global autoimmune treatment market, as it underscores the increasing adoption of specialized diagnostic tools, which play a pivotal role in early detection and personalized treatment, ultimately driving market growth and improving patient outcomes in autoimmune care
Frequently Asked Questions
The Asia-Pacific region is expected to witness the highest growth rate in the global autoimmune treatment market, driven by rapid advancements in healthcare infrastructure, increasing awareness about autoimmune diseases, and rising healthcare spending.
One prominent trend in the global autoimmune treatment market is the increasing adoption of biologic therapies and personalized medicine.
The increasing prevalence of autoimmune diseases is a major driver for the global autoimmune treatment market. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes are on the rise, contributing to the growing demand for effective treatment solutions.
